SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 232933.
  • 2
    Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 26270.
  • 3
    Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110: 15115.
  • 4
    Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes JR, Linder MW. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007; 53: 1199205.
  • 5
    Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79: 291302.
  • 6
    Majerus PWeaDMT. Blood coagulation and anticoagulation, thrombolytic, and antiplatelet drugs. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. ed. Brunton LL. New York: McGraw-Hill, 2006; 1477.
  • 7
    Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – rationale and perspectives. Thromb Res 2007; 120: 110.
  • 8
    Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095106.
  • 9
    Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 2009; 86: 4259.
  • 10
    Kunze KL, Trager WF, Warfarin-fluconazole III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 1996; 24: 42935.
  • 11
    Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 1989; 17: 26570.
  • 12
    Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF, Warfarin-fluconazole II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 4228.
  • 13
    O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974; 16: 34854.
  • 14
    Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 42430.
  • 15
    Chan E, McLachlan A, O'Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 28694.
  • 16
    Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81: 52938.
  • 17
    eMIMs. Warfarin Product Information. eMIMs Version 5.01.0093. CMP Medica Australia, 2008.
  • 18
    D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 6459.
  • 19
    Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 228593.
  • 20
    Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112: 101321.
  • 21
    Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 382734.
  • 22
    Bush E, Trager WF. High-yield synthesis of warfarin and its phenolic metabolites: new compounds. J Pharm Sci 1983; 72: 8301.
  • 23
    West BD, Preis S, Schroeder CH, Link KP. Studies on the 4-hydroxycoumarins. XVII.1a the resolution and absolute configuration of warfarin1b. J Am Chem Soc 1961; 83: 267679.
  • 24
    de Vries JX, Schmitz-Kummer E. Direct column liquid chromatographic enantiomer separation of the coumarin anticoagulants phenprocoumon, warfarin, acenocoumarol and metabolites on an [alpha]1-acid glycoprotein chiral stationary phase. J Chromatogr A 1993; 644: 31520.
  • 25
    Sharley NA, Yu AMC, Williams DB. Stability of mixtures formulated from warfarin tablets or powder. J Pharm Pract Res 2007; 37: 957.
  • 26
    Jensen BP, Chin PK, Begg EJ. Quantification of total and free concentrations of R- and S-warfarin in human plasma by ultrafiltration and LC-MS/MS. Anal Bioanal Chem 2011; 401: 218793.
  • 27
    US Department of Health and Human Services. US FDA Center for Drug Evaluation and Research M, USA. 2001). Guidance for industry: bioanalytical method validation.
  • 28
    Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 2006; 43: 7404.
  • 29
    Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010; 99: 30614.
  • 30
    Kerbusch T, Milligan PA, Karlsson MO. Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol 2004; 57: 17080.
  • 31
    Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483504.
  • 32
    Osman A, Enstrom C, Lindahl TL. Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype. Blood Coagul Fibrinolysis 2007; 18: 2936.
  • 33
    Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2012; 73: 6676.
  • 34
    Serlin MJ, Sibeon RG, Mossman S. Cimetidine: interaction with oral anticoagulants in man. Lancet 1979; 2: 31719.
  • 35
    O'Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med 1984; 144: 98991.
  • 36
    Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol 1987; 32: 16572.